Introduction: The higher prevalence and risk of hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are still observed in hemodialysis (HD) patients compared with healthy people. Interferons (IFNs) are known for their involvement in immune response. The addition of IFN-λ3 to immunization in animal models was shown to increase the immune response of T helper-1 cells.
Objectives: We studied whether polymorphisms of the IFN-λ3 gene (IFNL3) might be associated with the development of antibodies to HBV surface antigen [anti-HBs] in response to the HBV vaccination or HBV infection as well as spontaneous resolution of HCV infection in HD patients.
Patients and methods: The HD group consisted of 806 individuals without a history of HBV or HCV infection (of whom 672 developed anti-HBs in response to the HBV vaccination), 241 HBV-infected patients (of whom 186 developed anti-HBs), and 63 HCV-infected patients (including 39 HCV RNA-positive subjects). All patients were genotyped for IFNL3 rs8099917 and rs12979860 polymorphisms using a high-resolution melting curve analysis.
Results: The comparison of responders and nonresponders to HBV vaccination revealed no significant differences in the IFNL3 genotype distribution. In HBV-infected patients, the differences in the distribution of IFNL3 variants between anti-HBs-negative and anti-HBs-positive patients were also nonsignificant. Spontaneous HCV clearance was significantly less common in the carriers of the rs8099917 allele G or rs12979860 allele T, while the CT rs12979860_rs8099917 haplotype was more frequent (P = 0.02) in patients showing spontaneous HCV clearance.
Conclusions: In HD patients, the IFNL3 polymorphisms do not affect anti-HBs development in response to HBV infection or vaccination, but might be involved in the resolution of HCV infection.